Logo

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy

ARTICLES

Apalutamide Benefit Sustained in mCSPC Regardless of Next Therapy


MEDSCAPE

PUBLISHED: 24 FEBRUARY 2020


Early use of the androgen receptor antagonist apalutamide for metastatic castration-sensitive prostate cancer has a sustained carry-over benefit regardless of subsequent therapy, an exploratory analysis of the TITAN trial suggests.

explore_now-footer.png


Published

February 24, 2020

Categories

Oncology
CP-202103